2023 NMD4C Early Career Award Nominations Extended
We have extended the nomination submission deadline for our NMD4C Early-Career Investigator Awards! The new deadline is January 13th, 2023.
This initiative will allow NMD4C early-career members to be nominated for one of four awards, celebrating excellence and contribution to the neuromuscular field in both clinical and basic science streams.
The four early-career award categories that will be awarded for 2022 are:
- Early Career Researcher of the Year (Biomedical)
- Early Career Researcher of the Year (Clinical)
- Publication of the Year (Biomedical)
- Publication of the Year (Clinical)
If you wish to nominate yourself or an individual for any of these awards, please submit the following information via the nomination form here: https://www.surveymonkey.ca/r/NMD4C-ECawards.
You will be asked to include:
- Category for which you are nominating the individual.
- Brief bio sketch of the nominee. (any kind of biosketch accepted)
- Up to three clinical or research milestones of the nominee.
- Brief paragraph highlighting the achievements of the individual, and why you think they should receive the award.
- (For publication of the year biomedical/clinical) A PDF copy of the full publication you wish to nominate. *Publications from November 2021 – Present will be eligible.
Please complete this nomination form before the deadline of January 13, 2023 at 11:59pm ET.
The awards will be announced in January 2023 alongside the NMD4C/MDC neuromuscular clinical and postdoctoral research fellowships. If you have any questions, please feel free to reach out to communications coordinator James Davis at !
To be eligible for this award you must fall within the CIHR early-career criteria as being within five years of the date of a first independent appointment, and be a member of the NMD4C (if you are not a member, you can sign up here!)
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.